Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

Natalie Uy, Abhay Singh, Steven D. Gore, Thomas Prebet

Research output: Contribution to journalReview article

Abstract

Introduction: Hypomethylating agents (HMA) have played a pivotal role for treating myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological responses and delaying progression to leukemia. However, a vast majority of patients will experience treatment failure within 2 years, with poor prognoses and limited options, and management of this growing patient population remains unclear. Areas covered: With the introduction of new agents in the MDS field, a better understanding of the biology of MDS, and updated information on standard of care options (including allogeneic transplantation), we re-evaluate the global treatment strategy in MDS via novel agents, focusing in particular on investigational approaches for patients who fail to respond to HMA when applicable. This review aims to address two questions: what are reasonable alternatives to HMA in MDS, and what strategies can be used for patients experiencing HMA failure. Expert opinion/commentary: HMA therapy remains a mainstay of treatment, even if additional research is still warranted to maximize its benefits for the different groups of patients. The outcome of patients experiencing HMA failure remains grim, without standard of care, but several new approaches seem promising, as there is an increasing focus on studying treatments for patients refractory to HMA treatment.

Original languageEnglish (US)
Pages (from-to)1213-1224
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number12
DOIs
StatePublished - Aug 13 2017
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Recurrence
Standard of Care
Therapeutics
Homologous Transplantation
Expert Testimony
Treatment Failure
Leukemia
Research
Population

Keywords

  • Disease management
  • epigenetic modification
  • hypomethylating agent failure
  • hypomethylating agents
  • investigational agents
  • IPSS
  • myelodysplastic syndrome
  • treatment failure

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes : alternatives in the frontline and relapse settings. / Uy, Natalie; Singh, Abhay; Gore, Steven D.; Prebet, Thomas.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 12, 13.08.2017, p. 1213-1224.

Research output: Contribution to journalReview article

Uy, Natalie ; Singh, Abhay ; Gore, Steven D. ; Prebet, Thomas. / Hypomethylating agents (HMA) treatment for myelodysplastic syndromes : alternatives in the frontline and relapse settings. In: Expert Opinion on Pharmacotherapy. 2017 ; Vol. 18, No. 12. pp. 1213-1224.
@article{430e96f0fbda42da95c5152ed2f9bf4a,
title = "Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings",
abstract = "Introduction: Hypomethylating agents (HMA) have played a pivotal role for treating myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological responses and delaying progression to leukemia. However, a vast majority of patients will experience treatment failure within 2 years, with poor prognoses and limited options, and management of this growing patient population remains unclear. Areas covered: With the introduction of new agents in the MDS field, a better understanding of the biology of MDS, and updated information on standard of care options (including allogeneic transplantation), we re-evaluate the global treatment strategy in MDS via novel agents, focusing in particular on investigational approaches for patients who fail to respond to HMA when applicable. This review aims to address two questions: what are reasonable alternatives to HMA in MDS, and what strategies can be used for patients experiencing HMA failure. Expert opinion/commentary: HMA therapy remains a mainstay of treatment, even if additional research is still warranted to maximize its benefits for the different groups of patients. The outcome of patients experiencing HMA failure remains grim, without standard of care, but several new approaches seem promising, as there is an increasing focus on studying treatments for patients refractory to HMA treatment.",
keywords = "Disease management, epigenetic modification, hypomethylating agent failure, hypomethylating agents, investigational agents, IPSS, myelodysplastic syndrome, treatment failure",
author = "Natalie Uy and Abhay Singh and Gore, {Steven D.} and Thomas Prebet",
year = "2017",
month = "8",
day = "13",
doi = "10.1080/14656566.2017.1349100",
language = "English (US)",
volume = "18",
pages = "1213--1224",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Hypomethylating agents (HMA) treatment for myelodysplastic syndromes

T2 - alternatives in the frontline and relapse settings

AU - Uy, Natalie

AU - Singh, Abhay

AU - Gore, Steven D.

AU - Prebet, Thomas

PY - 2017/8/13

Y1 - 2017/8/13

N2 - Introduction: Hypomethylating agents (HMA) have played a pivotal role for treating myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological responses and delaying progression to leukemia. However, a vast majority of patients will experience treatment failure within 2 years, with poor prognoses and limited options, and management of this growing patient population remains unclear. Areas covered: With the introduction of new agents in the MDS field, a better understanding of the biology of MDS, and updated information on standard of care options (including allogeneic transplantation), we re-evaluate the global treatment strategy in MDS via novel agents, focusing in particular on investigational approaches for patients who fail to respond to HMA when applicable. This review aims to address two questions: what are reasonable alternatives to HMA in MDS, and what strategies can be used for patients experiencing HMA failure. Expert opinion/commentary: HMA therapy remains a mainstay of treatment, even if additional research is still warranted to maximize its benefits for the different groups of patients. The outcome of patients experiencing HMA failure remains grim, without standard of care, but several new approaches seem promising, as there is an increasing focus on studying treatments for patients refractory to HMA treatment.

AB - Introduction: Hypomethylating agents (HMA) have played a pivotal role for treating myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological responses and delaying progression to leukemia. However, a vast majority of patients will experience treatment failure within 2 years, with poor prognoses and limited options, and management of this growing patient population remains unclear. Areas covered: With the introduction of new agents in the MDS field, a better understanding of the biology of MDS, and updated information on standard of care options (including allogeneic transplantation), we re-evaluate the global treatment strategy in MDS via novel agents, focusing in particular on investigational approaches for patients who fail to respond to HMA when applicable. This review aims to address two questions: what are reasonable alternatives to HMA in MDS, and what strategies can be used for patients experiencing HMA failure. Expert opinion/commentary: HMA therapy remains a mainstay of treatment, even if additional research is still warranted to maximize its benefits for the different groups of patients. The outcome of patients experiencing HMA failure remains grim, without standard of care, but several new approaches seem promising, as there is an increasing focus on studying treatments for patients refractory to HMA treatment.

KW - Disease management

KW - epigenetic modification

KW - hypomethylating agent failure

KW - hypomethylating agents

KW - investigational agents

KW - IPSS

KW - myelodysplastic syndrome

KW - treatment failure

UR - http://www.scopus.com/inward/record.url?scp=85026886597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026886597&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1349100

DO - 10.1080/14656566.2017.1349100

M3 - Review article

C2 - 28675065

AN - SCOPUS:85026886597

VL - 18

SP - 1213

EP - 1224

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -